Royal Bank Of Canada reiterated their buy rating on shares of Core Laboratories (NYSE:CLB) in a research report report published on Friday morning. Royal Bank Of Canada currently has a $115.00 price target on the oil and gas company’s stock.

A number of other analysts also recently weighed in on CLB. ValuEngine downgraded shares of Core Laboratories from a hold rating to a sell rating in a research report on Friday. BidaskClub downgraded shares of Core Laboratories from a sell rating to a strong sell rating in a research report on Monday, August 14th. Cowen and Company reissued a hold rating and set a $100.00 target price on shares of Core Laboratories in a research report on Friday. Morgan Stanley decreased their target price on shares of Core Laboratories from $130.00 to $125.00 and set an overweight rating for the company in a research report on Monday, August 7th. Finally, Zacks Investment Research raised shares of Core Laboratories from a hold rating to a buy rating and set a $116.00 target price for the company in a research report on Monday, June 12th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $113.83.

Shares of Core Laboratories (NYSE:CLB) traded up 1.60% on Friday, hitting $89.59. 354,878 shares of the stock traded hands. Core Laboratories has a 1-year low of $86.55 and a 1-year high of $125.83. The stock has a 50 day moving average of $96.43 and a 200-day moving average of $105.73. The stock has a market cap of $3.95 billion, a PE ratio of 54.96 and a beta of 1.61.

Core Laboratories (NYSE:CLB) last released its earnings results on Monday, July 24th. The oil and gas company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.01. The business had revenue of $163.90 million during the quarter, compared to the consensus estimate of $168.23 million. Core Laboratories had a net margin of 13.86% and a return on equity of 61.31%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.35 EPS. On average, equities research analysts expect that Core Laboratories will post $2.09 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Core Laboratories (CLB) Receives “Buy” Rating from Royal Bank Of Canada” was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/core-laboratories-clb-receives-buy-rating-from-royal-bank-of-canada/1538407.html.

The business also recently declared a quarterly dividend, which was paid on Monday, August 14th. Investors of record on Monday, July 17th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 2.46%. The ex-dividend date was Thursday, July 13th. Core Laboratories’s payout ratio is currently 134.15%.

A number of large investors have recently added to or reduced their stakes in CLB. Goldman Sachs Group Inc. raised its stake in Core Laboratories by 156.2% in the first quarter. Goldman Sachs Group Inc. now owns 68,823 shares of the oil and gas company’s stock worth $7,951,000 after buying an additional 41,955 shares during the last quarter. Parsons Capital Management Inc. RI raised its stake in Core Laboratories by 15.4% in the first quarter. Parsons Capital Management Inc. RI now owns 10,436 shares of the oil and gas company’s stock worth $1,206,000 after buying an additional 1,394 shares during the last quarter. Morgan Stanley raised its stake in Core Laboratories by 17.5% in the first quarter. Morgan Stanley now owns 167,465 shares of the oil and gas company’s stock worth $19,346,000 after buying an additional 24,929 shares during the last quarter. Comerica Securities Inc. raised its stake in Core Laboratories by 22.5% in the first quarter. Comerica Securities Inc. now owns 2,529 shares of the oil and gas company’s stock worth $292,000 after buying an additional 465 shares during the last quarter. Finally, Motley Fool Wealth Management LLC raised its stake in Core Laboratories by 3.6% in the first quarter. Motley Fool Wealth Management LLC now owns 43,018 shares of the oil and gas company’s stock worth $4,969,000 after buying an additional 1,514 shares during the last quarter.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Analyst Recommendations for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.